Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase 3 Study Evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patient With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

NCT03593018 is registered in ClinicalTrials.gov with The Lymphoma Academic Research Organisation as lead sponsor.

NCT NCT03593018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03593018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase 3 Study Evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patient With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
Lead sponsor
The Lymphoma Academic Research Organisation
Phase
Phase 3
Overall status
Completed
Start date
November 9, 2018
Completion date
August 28, 2025
Enrollment
86 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

refractory angioimmunoblastic t-cell lymphoma, relapsed angioimmunoblastic t-cell lymphoma